In this exclusive interview transcript, Dr. Stanley Schwartz discusses SGLT-2s and evidence-based medicine: the risk of DKA in Type 2 diabetes is just five in 10,000, compared to a benefit of 38% reduction in cardiovascular mortality.

In this exclusive interview transcript, Dr. Stanley Schwartz discusses the proposed new diabetes classification, which seeks to not only just classify but to help in determining what type of treatment might be best for that patient.

Last week in our Clinical Series we had an excerpt from International Textbook of Diabetes Mellitus, 4th Ed., looking at Beta-Cell response to nonglucose secretagogues. This text dealt with how the beta cells might be affected by more than just glucose. We are learning more about how fat. protein, and non-insulin peptides might have effects we had never …

Are very-low carbohydrate, low saturated fat diets the best choice for A1c control?

Can C-peptide help attain adequate glycemic control in diabetes patients?

Can statins provide neuroprotective properties in diabetes patients?

What is the association between obesity and cardiovascular risks?

How can diabetes progression be prevented in patients with nondiabetic hyperglycemia?

At least an hour of physical activity needed to offset risk for several chronic conditions and mortality.

How often do you prescribe or recommend a sulfonylurea for a new type 2 patient? 1) Often 2) About 50% 3) Almost Never Follow the link to share your opinion!